1. Home
  2. SLN vs BYND Comparison

SLN vs BYND Comparison

Compare SLN & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • BYND
  • Stock Information
  • Founded
  • SLN 1994
  • BYND 2009
  • Country
  • SLN United Kingdom
  • BYND United States
  • Employees
  • SLN N/A
  • BYND N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • BYND Packaged Foods
  • Sector
  • SLN Health Care
  • BYND Consumer Staples
  • Exchange
  • SLN Nasdaq
  • BYND Nasdaq
  • Market Cap
  • SLN 281.0M
  • BYND 258.5M
  • IPO Year
  • SLN N/A
  • BYND 2019
  • Fundamental
  • Price
  • SLN $5.92
  • BYND $3.45
  • Analyst Decision
  • SLN Buy
  • BYND Sell
  • Analyst Count
  • SLN 5
  • BYND 3
  • Target Price
  • SLN $32.60
  • BYND $4.00
  • AVG Volume (30 Days)
  • SLN 111.7K
  • BYND 1.9M
  • Earning Date
  • SLN 08-14-2025
  • BYND 08-06-2025
  • Dividend Yield
  • SLN N/A
  • BYND N/A
  • EPS Growth
  • SLN N/A
  • BYND N/A
  • EPS
  • SLN N/A
  • BYND N/A
  • Revenue
  • SLN $27,701,000.00
  • BYND $319,580,000.00
  • Revenue This Year
  • SLN N/A
  • BYND N/A
  • Revenue Next Year
  • SLN N/A
  • BYND $3.36
  • P/E Ratio
  • SLN N/A
  • BYND N/A
  • Revenue Growth
  • SLN N/A
  • BYND N/A
  • 52 Week Low
  • SLN $1.97
  • BYND $2.23
  • 52 Week High
  • SLN $22.47
  • BYND $9.24
  • Technical
  • Relative Strength Index (RSI)
  • SLN 58.35
  • BYND 60.62
  • Support Level
  • SLN $5.33
  • BYND $3.23
  • Resistance Level
  • SLN $6.00
  • BYND $3.61
  • Average True Range (ATR)
  • SLN 0.44
  • BYND 0.17
  • MACD
  • SLN -0.03
  • BYND -0.01
  • Stochastic Oscillator
  • SLN 64.07
  • BYND 64.44

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: